The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population-based, age-stratified sero-epidemiological investigation.
Burkina Faso
COVID-19
SARS-CoV-2
WHO UNITY study
infectious disease
population-based seroprevalence
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
08
09
2023
received:
04
03
2023
accepted:
05
10
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso). We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2. Data were analysed with descriptive and comparative statistics. We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test-adjusted seroprevalence for SARS-CoV-2 antibodies was (67.8% [95% CI 65.9-70.2]) (N = 3553/3982). Seroprevalence was highest among participants aged 15-18 years old (74.2% [95% CI 70.5-77.5]) (N = 465/627), compared with those aged 10-14 years old (62.6% [95% CI 58.7-66.4]) (N = 395/631), or those over 18 (67.6% [95% CI 66.2-69.1]) (N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10-18 years old who tested positive for SARS-CoV-2 antibodies experienced no clinical COVID-19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old. This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS-CoV-2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS-CoV-2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso).
METHODS
METHODS
We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2. Data were analysed with descriptive and comparative statistics.
RESULTS
RESULTS
We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test-adjusted seroprevalence for SARS-CoV-2 antibodies was (67.8% [95% CI 65.9-70.2]) (N = 3553/3982). Seroprevalence was highest among participants aged 15-18 years old (74.2% [95% CI 70.5-77.5]) (N = 465/627), compared with those aged 10-14 years old (62.6% [95% CI 58.7-66.4]) (N = 395/631), or those over 18 (67.6% [95% CI 66.2-69.1]) (N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10-18 years old who tested positive for SARS-CoV-2 antibodies experienced no clinical COVID-19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old.
CONCLUSION
CONCLUSIONS
This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS-CoV-2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS-CoV-2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID-19.
Identifiants
pubmed: 38019697
doi: 10.1111/irv.13216
pmc: PMC10655778
pii: IRV13216
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13216Subventions
Organisme : ANRS (France Recherche Nord&Sud Sida-HIV Hépatites)
ID : ANRS-COV13/EMuLCOVID-19
Organisme : Canadian Institutes of Health Research (CIHR)
Organisme : Institut National de Santé Publique du Québec (INSPQ)
Organisme : Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University
Informations de copyright
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
Glob Soc Policy. 2015 Dec;15(3):345-348
pubmed: 26635505
Nat Rev Immunol. 2021 Aug;21(8):469-470
pubmed: 34168345
J Clin Virol. 2020 Nov;132:104633
pubmed: 32927357
Nature. 2021 Mar;591(7851):520-522
pubmed: 33737753
Global Health. 2021 May 7;17(1):54
pubmed: 33962651
Malar J. 2020 Dec 23;19(1):457
pubmed: 33357220
mSphere. 2021 Dec 22;6(6):e0068521
pubmed: 34817236
Nat Commun. 2021 Oct 6;12(1):5851
pubmed: 34615863
BMC Infect Dis. 2021 Sep 3;21(1):896
pubmed: 34479501
BMJ Glob Health. 2020 May;5(5):
pubmed: 32451367
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Pan Afr Med J. 2021 Jan 05;38:6
pubmed: 33520075
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
Influenza Other Respir Viruses. 2022 Jan;16(1):7-13
pubmed: 34611986
BMC Public Health. 2022 Sep 5;22(1):1676
pubmed: 36064368
Glob Health Sci Pract. 2021 Sep 30;9(3):433-443
pubmed: 34593571
Sci Data. 2023 Jun 7;10(1):367
pubmed: 37286690
Lancet Glob Health. 2021 May;9(5):e588-e589
pubmed: 33609481
Clin Infect Dis. 2022 Mar 23;74(6):1030-1038
pubmed: 34185847
Int J Infect Dis. 2021 Jan;102:577-583
pubmed: 33176202
Eur J Med Res. 2022 Jun 2;27(1):81
pubmed: 35655237
PLoS One. 2021 Jun 23;16(6):e0252617
pubmed: 34161316
J Gerontol Soc Work. 2020 Aug-Oct;63(6-7):717-723
pubmed: 32808585
Int J Infect Dis. 2021 Nov;112:25-34
pubmed: 34481966